| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03207867 2017-000241-49 Details | 2024-03-01 Interventional | 2 | 315 | Spartalizumab Carcinoma, Rena… Lymphoma Lymphoma, Non-H… Triple Negative… DLBCL, Diffused… Head and Neck C… MSS, Microsatel… Melanoma NSCLC, Non Smal… Pancreatic Canc… RCC, Renal Cell… TNBC, Triple Ne… Urothelial Canc… mCRPC, Metastat… | Sponsor decision - | |||
| NCT05481112 Details | 2024-02-29 Interventional | 4 | 0 | Buprenorphine Opioid-Related … Opioid Use Diso… | This study was not initiated due to policy changes in Massachusetts (the proposed study sites). - | |||
| NCT04629196 Details | 2024-02-29 Interventional | 4 | 25 | Ustekinumab Crohn Disease | Other effective drugs have been introduced to market since the beginning of the study. - | |||
| NCT03711279 Details | 2024-02-29 Interventional | 2 | 99 | Apatinib Sarcoma | Sponsor R & D Strategy Adjustment - | |||
| NCT03585465 Details | 2024-02-29 Interventional | 1/2 | - | Capecitabine Cyclophosphamid… Nivolumab Vinblastine Neoplasms Childhood Solid… | Interim analysis - | |||
| NCT05703555 2022-003451-34 Details | 2024-02-28 Interventional | 2 | 0 | Maytansine Stomach Neoplas… Metastatic Brea… Metastatic Gast… Metastatic Lung… | Due to the decision to discontinue the global clinical development program of tusamitamab
ravtansine - | |||
| NCT05683574 Details | 2024-02-28 Interventional | 3 | 0 | Amitriptyline Cyclobenzaprine Etoricoxib Third Molar Ext… | Change in study strategy. - | |||
| NCT05643573 2022-000758-28 2023-503794-38 Details | 2024-02-28 Interventional | 3 | 14830 | Apixaban Atrial Fibrilla… Embolism Stroke Prevention of S… | Independent Data Monitoring Committee (IDMC) recommendation to stop the study - | |||
| NCT05405686 Details | 2024-02-28 Interventional | 4 | 0 | Follicle Stimul… Poor Response t… | withdrawn due to practical reasons - | |||
| NCT05331053 Details | 2024-02-28 Interventional | 4 | 6 | Atorvastatin Endometriosis | COVID halting human subjects research and preliminary data from this proposal were used to
submit an NIH grant. The NIH grant was funded and 3 other protocols were launched. - | |||
| NCT04936971 Details | 2024-02-28 Interventional | 4 | 0 | Everolimus Mycophenolic Ac… Cytomegalovirus… Kidney Transpla… | Impossibility to perform tests (elispot) of the study due to change of location of laboratory - | |||
| NCT04921358 2022-001779-15 Details | 2024-02-28 Interventional | 3 | 377 | Docetaxel Tislelizumab Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to
voluntarily terminate the study. - | |||
| NCT04058132 Details | 2024-02-28 Interventional | 2 | [9 Refs] | 1 | Sildenafil Citr… Brain Injuries Brain Injuries,… Wounds and Inju… Traumatic Brain… | funding ran out after unanticipated length of time ( for IRB approval, CRADA, and start letter - | ||
| NCT03792503 Details | 2024-02-28 Interventional | 4 | 0 | Apatinib Pemetrexed Carcinoma, Non-… Lung Neoplasms Advanced Non-sq… | abandon - | |||
| NCT03190239 Details | 2024-02-28 Interventional | 2 | 0 | Apatinib Pemetrexed Carcinoma, Non-… Lung Neoplasms Advanced Non-sq… | abandon - | |||
| NCT03179163 Details | 2024-02-28 Interventional | 1/2 | 10 | Captopril Enalapril Hydrochlorothia… Essential Hyper… Hypertension Hypertension,Es… | COVID shut down human subjects research and then the grant funding expired - | |||
| NCT00609154 Details | 2024-02-28 Interventional | 1/2 | 20 | Glucagon Glucagon-Like P… Incretins Diabetes Mellit… Type 2 Diabetes | Per source documents the study was terminated well in advance of targeted enrollment. A method
for the analysis of insulin and proinsulin samples was never fully developed and validated.
Study terminated upon expiration of IRB approval - | |||
| NCT06083675 Details | 2024-02-26 Interventional | 3 | 0 | Empagliflozin Metformin Semaglutide Diabetes Mellit… Diabetes Mellit… | Due to internal reprioritization, trial was cancelled. - | |||
| NCT05700630 Details | 2024-02-26 Interventional | 1 | 0 | Vorinostat Communicable Di… Infections Viremia ART Cd4+ Lymphocyte… HIV-1-infection Interleukin Lymphoid Tissue… | Abandoned - | |||
| NCT05474690 Details | 2024-02-26 Interventional | 3 | 0 | Carboplatin Cyclophosphamid… Docetaxel Epirubicin Pertuzumab Trastuzumab Breast Neoplasm… Breast Cancer HER2-positive B… | The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment
guide. The treatment plan ECHP-THP in this study is not the optimal treatment plan, therefore
this study was terminated. - |